Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

40.75 -0.11 (-0.27%)
Streaming Delayed Price Updated: 9:33 AM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 142,225
Open 40.76
Bid (Size) 40.74 (26)
Ask (Size) 40.76 (1)
Prev. Close 40.86
Today's Range 40.70 - 40.80
52wk Range 33.67 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 3.54%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
From Alector, Inc.
Via GlobeNewswire

Performance

YTD
+8.64%
+8.64%
1 Month
-4.21%
-4.21%
3 Month
+0.49%
+0.49%
6 Month
-4.86%
-4.86%
1 Year
+8.06%
+8.06%

More News

Read More
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
Via Benzinga
Exposures Product Safety
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
Via Benzinga
Exposures Product Safety
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
From GSK plc
Via Business Wire
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Via Investor's Business Daily
Topics Death
Exposures Death
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
Via Investor's Business Daily
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
Via Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
Via Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug
Via Benzinga
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
Via FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
From FN Media Group LLC
Via GlobeNewswire
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Via Investor's Business Daily
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Via Benzinga
Exposures COVID-19
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
From GSK plc
Via Business Wire
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.